Effects of Liraglutide on Abdominal Fat Distribution and Glucose Metabolism in Chinese Subjects with Obesity

Overview

Journal Diabetol Metab Syndr

Publisher Biomed Central

Specialty Endocrinology

Date 2024 Dec 20

PMID 39707524

Authors

Mengyang Du

Jiang Yue

Yicheng Qi

Shengyun He

Xiaobing Lu

Minglan Yang

Lihua Wang

Qing Lu

Jing Ma

Affiliations

Soon will be listed here.

Abstract

Aims: To observe the effects of liraglutide on abdominal fat distribution in Chinese subjects with obesity in 12 weeks, and further to explore the correlation between abdominal fat content and glucose metabolism after monotherapy.

Methods: This study recruited 71 obese subjects. All the subjects have received liraglutide monotherapy (0.6 mg-1.8 mg/d) for 12 weeks. Clinical assessment, laboratory assays and magnetic resonance imaging (MRI) examination were accessed at baseline and after 12 weeks treatment. MRI was applied to measure abdominal fat distribution, calculated by proton-density fat fraction (PDFF).

Results: After 12 weeks of liraglutide monotherapy, body weight in the obese participants decreased significantly (P < 0.001). Fasting blood glucose (FBG) levels, 2 h post-load blood glucose (2hPBG) levels, and glycosylated hemoglobin (HbA1c) were remarkably improved after liraglutide monotherapy (all P < 0.001). Subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) were significantly reduced after liraglutide monotheraphy (both P < 0.001). There was a notable reduction in liver fat content (LFC) after liraglutide monotherapy (P < 0.001). In the further analysis, LFC was greater in obese subjects with impaired glucose regulation (IGR) at baseline compared to those with normal glucose tolerance (NGT) (P = 0.002). The LFC reduction in IGR group was significantly greater than those in NGT group after liraglutide treatment (P < 0.001). Pearson correlation analysis showed that reduction of LFC was significantly correlated with improvement of FBG (r = 0.587, P < 0.001) and HbA1c (r = 0.607, P < 0.001) in obese patients.

Conclusion: LFC was significantly reduced after liraglutide monotherapy for 12 weeks in subjects with obesity. The LFC reduction is likely to be associated with IGR remission in obese subjects.

References

Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M . Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2014; 45(3):269-78. DOI: 10.1111/hepr.12351. View

Goossens G . The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function. Obes Facts. 2017; 10(3):207-215. PMC: 5644968. DOI: 10.1159/000471488. View

Davies M, Bergenstal R, Bode B, Kushner R, Lewin A, Skjoth T . Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015; 314(7):687-99. DOI: 10.1001/jama.2015.9676. View

Kuriyama T, Ishibashi C, Kozawa J, Y Baden M, Horii T, Niki A . Effects of liraglutide on intrapancreatic fat deposition in patients with type 2 diabetes. Clin Nutr ESPEN. 2024; 59:208-213. DOI: 10.1016/j.clnesp.2023.12.005. View

Fan S, Shi X, Yao J, Zhong M, Feng P . The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Rev Esp Enferm Dig. 2020; 112(8):627-635. DOI: 10.17235/reed.2020.6392/2019. View

Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges J . Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007; 30(6):1608-10. DOI: 10.2337/dc06-2593. View

Feinglos M, Saad M, Pi-Sunyer F, An B, Santiago O . Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med. 2005; 22(8):1016-23. DOI: 10.1111/j.1464-5491.2005.01567.x. View

Lara-Castro C, Luo N, Wallace P, Klein R, Garvey W . Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes. 2005; 55(1):249-59. View

Zhou B . Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults--study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002; 15(1):83-96. View

10.

Lim U, Ernst T, Buchthal S, Latch M, Albright C, Wilkens L . Asian women have greater abdominal and visceral adiposity than Caucasian women with similar body mass index. Nutr Diabetes. 2013; 1:e6. PMC: 3302135. DOI: 10.1038/nutd.2011.2. View

11.

Oliveira F, Bauer E, Ribeiro C, Pereira S, Beserra B, Wajner S . Liraglutide Activates Type 2 Deiodinase and Enhances β3-Adrenergic-Induced Thermogenesis in Mouse Adipose Tissue. Front Endocrinol (Lausanne). 2022; 12:803363. PMC: 8771968. DOI: 10.3389/fendo.2021.803363. View

12.

Tejani S, McCoy C, Ayers C, Powell-Wiley T, Despres J, Linge J . Cardiometabolic Health Outcomes Associated With Discordant Visceral and Liver Fat Phenotypes: Insights From the Dallas Heart Study and UK Biobank. Mayo Clin Proc. 2021; 97(2):225-237. PMC: 8818017. DOI: 10.1016/j.mayocp.2021.08.021. View

13.

Despres J . Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012; 126(10):1301-13. DOI: 10.1161/CIRCULATIONAHA.111.067264. View

14.

Svane M, Johannesen H, Hansen A, Martinussen C, Bojsen-Moller K, Hansen M . Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight. Int J Obes (Lond). 2022; 46(11):2058-2062. DOI: 10.1038/s41366-022-01207-y. View

15.

Zheng R, Li M, Xu M, Lu J, Wang T, Dai M . Chinese Adults Are More Susceptible to Effects of Overall Obesity and Fat Distribution on Cardiometabolic Risk Factors. J Clin Endocrinol Metab. 2021; 106(7):e2775-e2788. DOI: 10.1210/clinem/dgab049. View

16.

van Eyk H, Paiman E, Bizino M, de Heer P, Geelhoed-Duijvestijn P, Kharagjitsingh A . A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients. Cardiovasc Diabetol. 2019; 18(1):87. PMC: 6615254. DOI: 10.1186/s12933-019-0890-5. View

17.

Peradze N, Farr O, Perakakis N, Lazaro I, Sala-Vila A, Mantzoros C . Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over,.... Cardiovasc Diabetol. 2019; 18(1):141. PMC: 6823961. DOI: 10.1186/s12933-019-0945-7. View

18.

Eslam M, Sarin S, Wong V, Fan J, Kawaguchi T, Ahn S . The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020; 14(6):889-919. DOI: 10.1007/s12072-020-10094-2. View

19.

Kadouh H, Chedid V, Halawi H, Burton D, Clark M, Khemani D . GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity. J Clin Endocrinol Metab. 2019; 105(5). PMC: 7105351. DOI: 10.1210/clinem/dgz140. View

20.

Nasr P, Fredrikson M, Ekstedt M, Kechagias S . The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. Liver Int. 2020; 40(5):1069-1078. DOI: 10.1111/liv.14414. View